FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Imaging Diagnostic Systems, Inc., (OTCBB:IMDS - News) announced today that Socrate Medical SRL located in Milan, Italy has been selected as a distributor for the CT Laser Mammography (CTLM®) system in Northern and Central Italy. The company will market the system to the private and public sector of these regions.
“The partnership with CTLM paves the ground to pursue the broader social objectives such as the massive extension of the screening programs to the women under age 49. We will pursue this with the full involvement of the radiologists by utilizing the CTLM systems currently installed and collaborating with present users,” stated Giulio Ottavio, Battagliarin CEO of Socrate Medical SRL. “We want to contribute to reaching the goal of reducing the mortality rate among women by adding the latest technical advancements of breast cancer detection devices to the medical community,” continued Giulio Ottavio Battagliarin, CEO of Socrate Medical SRL.
Based in Milan and established in 2003, Socrate Medical strives to distribute and market the latest and most advanced diagnostic imaging technologies while serving as a single point of contact to meet clients’ specific requirements. Socrate Medical has been a forerunner in the identification and proposal of non radiant solutions suitable for targeted early diagnosis in women aged between 20 and 49. This has been done in collaboration with prestigious institutions, such as the Macchi Foundation of Varese, the Zucchi Hospital in Monza and the IPA in Rome, where 5,000 women will be screened each year. Socrate Medical has proposed solutions involving breast cancer detection equipment coupled with advance ultrasound scanners.
“We are pleased to have Socrate Medical as our representative in North and Central Italy, which have been important markets for IDSI,” stated IDSI Senior Vice President Deborah O’Brien. “The enthusiasm and interest that this emerging company is capable of generating could be significant.”
IDSI exhibited at the European Congress of Radiology (ECR 2009), where they met with various distribution companies interested in marketing the CTLM system throughout Europe. The company will continue to select additional distributors in strategic locations.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a patented new breast imaging system that utilizes continuous wave laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our corporate website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
